Work

A New Era in Therapeutics: Current Status of RNA Interference-Based Drugs

Year: 2026
Type: article
Abstract: RNA interference (RNAi) is a post-transcriptional gene silencing mechanism that regulates gene expression through sequence-specific degradation or translational inhibition of mRNA. Since its discovery, RNAi has emerged as a powerful therapeutic strategy due to its ability to selectively silence disease-causing genes that are often inaccessible to conventional small-molecule drugs. The clinical efficacy of RNAi technology is evidenced by the approval of multiple siRNA-based therapeutics for the treatment of various diseases. These include patisiran and vutrisiran for hereditary transthyretin amyloidosis, inclisiran for hypercholesterolemia, fitusiran for haemophilia A and B, givosiran for acute hepatic porphyria, and lumasiran and nedosiran for primary hyperoxaluria. Concurrently, a significant number of RNAi therapeutics are currently undergoing clinical trials for metabolic, cardiovascular, neurological, renal, pulmonary diseases and oncological area. Despite these advances, the clinical translation of RNAi therapeutics is limited by several challenges, including off-target effects, immune activation, and difficulties associated with efficient and targeted delivery. Ongoing research focuses on improving siRNA design, chemical modification, and delivery strategies in order to enhance specificity, reduce immunogenicity, and achieve effective delivery to target tissues. In conclusion, RNA interference has become more significant and expanding therapeutic approach with considerable implications for future drug development.
Source: Pharmata
Language: English
Open Access status: diamond
OpenAlex ID: W7226025577
FWCI:
Cites: 43
Cited by:
Related to: 10